SBP-101

SBP-101 is a therapeutic cancer vaccine candidate being developed by SML Biopharm for the treatment of cervical cancer. Currently in the preclinical stage of development, the vaccine is designed to stimulate the host's immune system to identify and eliminate malignant cells associated with cervical cancer. While specific antigen targets have not been publicly disclosed in pipeline summaries, therapeutic vaccines for this indication typically target oncoproteins associated with Human Papillomavirus (HPV), the primary causative agent of cervical cancer. SML Biopharm is utilizing its proprietary vaccine platform technologies to advance this candidate through candidate optimization and preclinical testing.